OGT

Oxford Gene Technology is a genomic diagnostics company developing and manufacturing hybridisation-based reagents and assays for clinical and research laboratories.

Its product portfolio spans FISH probes, chromosomal microarrays and next-generation sequencing panels, enabling detection of chromosomal abnormalities and somatic mutations across haematological malignancies, solid tumours, cytogenetics and rare diseases.

A FISH probe for KMT2A rearrangement in acute leukaemia received FDA De Novo classification as a companion diagnostic in 2024.